Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced that it presented updated clinical data in a poster session at the 43rd Annual Meeting of The American Society of Clinical Oncology (ASCO) on its lead anticancer agent Cloretazine(R) (VNP40101M) as a single agent in a Phase II trial in patients with relapsed or refractory small cell lung cancer.

The Phase II trial evaluates Cloretazine(R) (VNP40101M) in two separate subpopulations of small cell lung cancer: (i) sensitive relapse disease and (ii) refractory disease. Sensitive relapse disease is defined as relapse after three months of first-line therapy and refractory disease is defined as relapse within three months of first-line therapy. Data are presented on a total of 48 evaluable patients: (i) 20 patients in the sensitive relapse arm and (ii) 28 patients in the refractory arm.

Patients on the trial initially received 125 mg/m2 of Cloretazine(R) (VNP40101M) weekly for three weeks, every six weeks. This dose was later reduced by protocol amendment to 100 mg/m2 weekly for three weeks every six weeks due to the incidence of grade 3 and 4 thrombocytopenia at the initial dose level.

Of the 20 evaluable patients on the sensitive relapse arm, there have been 6 patients with partial response and one patient awaiting confirmation of response (overall, 35% response rate), and 3 patients have stable disease. Four of 13 sensitive relapse patients responded at the 125 mg/m2 dose level and 3 of 7 sensitive relapse patients responded at the 100 mg/m2 dose level. Of the 28 patients with refractory disease treated with Cloretazine(R) (VNP40101M), 1 patient achieved a partial response and 3 patients have demonstrated stable disease.

A total of 55 patients were evaluable for toxicity. Grade 3 and 4 thrombocytopenia was observed in 14 of 31 patients (45%) at the 125 mg/m2 dose level. Thrombocytopenia was su
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/22/2014)... Sept. 22, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... has been appointed President and Chief Executive Officer, effective ... has stepped down from his executive and Board roles ... through the first quarter of 2016.  ...
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Diclofenac Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The diclofenac ...
(Date:9/22/2014)... SHENZHEN, China , Sept. 22, 2014 China Nepstar ... "Company"), a leading retail drugstore chain in China ... that it will hold its 2014 Annual General Meeting of Shareholders ... The AGM will be held at the meeting room of the ... District, Shenzhen , Guangdong Province ...
Breaking Medicine Technology:Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5Global and Chinese Diclofenac Industry Report 2014 2China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2
... 3, 2010 The American College of Radiology (ACR) distributed ... ( MCR5 ) educational CD-ROM free of charge to physicians ... Mammography Case Review ( MCR5 ... improve their skills regarding the detection of cancers and other ...
... contract research organization will expand its operations in Chester County ... the Department of Community and Economic Development announced today. ... in Wayne, purchase new equipment and provide employee training. The ... three years and retain 80 existing positions.   ...
Cached Medicine Technology:ACR Distributes Free High-Tech Mammography Education Tool to NY Facilities 2Research Facility Expansion Will Create, Retain More than 150 Jobs in Chester County 2
(Date:9/22/2014)... 22, 2014 (HealthDay News) -- Teens and young adults ... behavioral counseling to help prevent risky sexual behaviors, according ... Force. Every year, about 20 million new sexually ... the United States. About half involve people between 15 ... Its new report, published Sept. 22 in ...
(Date:9/22/2014)... study pulls back the curtain on one of the ... and income between physicians who perform operations, procedures or ... perception, the research indicates, the physician payment system is ... doctors. , The new findings counter the widely held ... explains why doctors who perform procedures often earn nearly ...
(Date:9/22/2014)... September 22, 2014 Manhattan residents who ... side of the hip , which could be bursitis ... This treatment is now offered at New York Dynamic ... called trochanteric bursitis, occurs when the trochanteric bursa becomes ... in the hip, between the iliotibial band and the ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 ... 6 months and older be vaccinated for the upcoming flu ... vaccine recommendations to advise that the youngest kids should have ... also wants parents of children aged 2 to 8 to ... the flu shot if it,s readily available. "It,s important ...
(Date:9/22/2014)... MA Up to 40 percent of patients undergoing ... fail to remove all the cancerous tissue in the ... (BWH) have successfully tested a tool they developed that ... normal tissue, thereby decreasing the chances for repeat operations. ... the week of September 22, 2014 in the ...
Breaking Medicine News(10 mins):Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:The fine line between breast cancer and normal tissues 2
... States,Agency for International Development (USAID) is pleased to ... reduces the risk of,diarrhea. Sur,Eau is a water ... can be added to water immediately before,use and ... children and,people living with HIV and AIDS -- ...
... SAN DIEGO, April 25 SynergEyes, Inc., of ... designed for people,who need further vision correction after ... designed for patients who,have experienced some type of ... Every year, millions of people undergo LASIK ...
... Nonprofit Health Systems Research Institute as New Vice ... ... leader,and advocate on HIV/AIDS issues, has joined the nonprofit Altarum Institute,as Vice ... began the search for someone to lead our Community Health,Systems Group, I ...
... Comments Made by TV Game Show Host Spark Controversy, ... long-time host of,the television game show "The Price Is ... (CDOC), a non-profit group formed to,support responsible dog ownership. ... neuter law that went into effect this month in ...
... North Carolina-based Oaks,Development Group announced today ... Olympia Avenue, in Punta Gorda, Florida. The,29,927-square-foot ... near,Charlotte Regional Medical Center and currently includes ... converted to Oaks, unique,tenant-ownership model., Oaks, ...
... Tanzania, April 25 Today is a,great day for the ... a day to,celebrate. We celebrate because of the possibilities that ... by the United,Nations Secretary General His Excellency Ban Ki-Moon, presents ... is implemented to the,letter, millions of lives will be saved ...
Cached Medicine News:Health News:Disinfecting Water Saves Lives in Rwanda 2Health News:SynergEyes Hybrid Contact Lenses Provide a Vision Solution for Post-LASIK Patients 2Health News:Prominent Advocate on HIV/AIDS Issues Joins Altarum Institute 2Health News:Bob Barker's 'Right' to Free Speech Comes with a 'Price' 2Health News:Oaks Development Group Acquires Medical Office Building in Punta Gorda, Florida 2Health News:Statement by H.E. Jakaya Mrisho Kikwete, President of the United Republic of Tanzania, and Chairman of the African Union, in Response to UN-SG Call to Action on Malaria 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: